TL;DR: MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded in mitochondrial DNA. In animal and cell studies it activates the AMPK metabolic-sensor pathway, improving insulin sensitivity and fat metabolism. It rises with exercise and falls with age, making it a research target for metabolic and longevity science. Human evidence remains early.
What MOTS-c actually is
MOTS-c stands for “mitochondrial open reading frame of the 12S rRNA type-c.” Unlike almost every other peptide discussed in longevity research, it is not encoded by nuclear DNA. Instead, its 16-amino-acid sequence is written into a short open reading frame within the mitochondrial 12S ribosomal RNA gene, one of only a handful of peptides known to be produced this way.
That origin matters. Mitochondria are usually described as the cell’s power plants, but MOTS-c reframes them as signalling hubs. The peptide is released from mitochondria into the cytoplasm and bloodstream, where it behaves as a retrograde signal, essentially a message sent from the mitochondria back to the rest of the cell and to distant tissues. Under metabolic or oxidative stress, MOTS-c can translocate to the cell nucleus and influence stress-adaptive gene expression.
Its best-characterised action is metabolic. Preclinical work indicates MOTS-c interferes with the folate-methionine one-carbon cycle, causing the purine-synthesis intermediate AICAR to accumulate. AICAR is a well-known activator of AMP-activated protein kinase (AMPK), the cell’s master energy sensor. Through AMPK, MOTS-c is reported to promote glucose uptake in skeletal muscle, support fatty-acid oxidation, and shift cells toward an energy-conserving metabolic state.
What the research shows
The foundational paper came from Lee and colleagues in Cell Metabolism (2015), who first characterised MOTS-c and showed that systemic treatment in mice improved insulin sensitivity and protected against diet-induced obesity and age-dependent insulin resistance. Skeletal muscle appeared to be the primary target tissue.
A frequently cited follow-up is Reynolds and colleagues in Nature Communications (2021). In mice, MOTS-c treatment in older animals nearly doubled running capacity on a treadmill and improved measures of muscle homeostasis. Importantly, the same study included a small human arm: in young male volunteers, an acute bout of cycling raised MOTS-c messenger RNA in skeletal muscle roughly 12-fold and increased circulating MOTS-c around 1.6-fold. This established MOTS-c as an exercise-responsive peptide in humans, not only in rodents.
Fold-change after an acute bout of cycling in young male volunteers.
Kim and colleagues (Physiological Reports, 2019) reported that MOTS-c acts as a regulator of plasma metabolites and enhances whole-body insulin sensitivity in mice, with roughly a 30% increase in the glucose infusion rate needed to maintain normal blood sugar during insulin clamping. Human observational data also show that circulating MOTS-c tends to decline with chronological age.
Here is the honest framing. The overwhelming majority of positive MOTS-c findings come from cell culture and mouse models. Direct, well-powered human clinical trials of native MOTS-c are scarce. The most substantial human-oriented data involve engineered MOTS-c analogues with improved pharmacokinetics rather than the unmodified peptide, and published outcomes remain preliminary. No health authority has approved MOTS-c as a treatment for any condition, and it is not a licensed medicine in the EU. It is also worth noting that MOTS-c was added to the World Anti-Doping Agency Prohibited List effective January 2024, which is relevant context for anyone in tested sport.
How MOTS-c differs from SS-31 and NAD+
MOTS-c is often grouped with other “mitochondrial” compounds, but the mechanisms are genuinely different. The table below summarises the contrast at a research level. None of this is a usage recommendation.
| Feature | MOTS-c | SS-31 (elamipretide) | NAD+ (and precursors) |
|---|---|---|---|
| Class | Mitochondrial-derived signalling peptide (16 aa) | Synthetic mitochondria-targeting tetrapeptide (4 aa) | Coenzyme / redox cofactor |
| Primary mechanism | Activates AMPK via the AICAR pathway; nuclear signalling | Binds cardiolipin in the inner membrane, stabilising cristae | Fuels sirtuins and redox reactions; central to energy metabolism |
| Main research focus | Insulin sensitivity, metabolism, exercise, aging | Cristae structure, bioenergetics, cardiac and muscle research | Cellular energy, DNA-repair signalling, aging pathways |
| Where it acts | Whole-body metabolic tissues (esp. muscle) | Directly at the inner mitochondrial membrane | Nearly every cell and metabolic pathway |
| Evidence maturity | Mostly preclinical, limited human data | Multiple clinical trials, mixed readouts | Extensive basic science, growing human trials |
In short, SS-31 is a structural stabiliser that concentrates in damaged mitochondrial membranes, whereas MOTS-c is a metabolic reprogramming signal that works largely through AMPK. NAD+ is not a peptide at all but a cofactor that underpins the reactions both peptides influence. Researchers comparing these often study them for overlapping goals through non-overlapping routes. You can read more about the membrane-targeting approach on our reference page for SS-31 5mg and about the cofactor approach on our NAD+ 1000mg profile.
Why the exercise and longevity link is interesting
The most compelling narrative around MOTS-c is that it may be one molecular messenger behind why exercise is metabolically protective. Because endogenous MOTS-c rises sharply with acute exercise and declines with age, it sits at the intersection of two of the most robust findings in aging biology: exercise improves metabolic health, and metabolic dysfunction accelerates aging. AMPK activation, MOTS-c’s core mechanism, is also the target of well-studied interventions such as caloric restriction and the drug metformin.
This is why MOTS-c is studied as a candidate “exercise-mimetic” signal in longevity research. It is not, on current evidence, an established anti-aging therapy. The gap between an intriguing mouse phenotype and a proven human benefit is large, and MOTS-c has not yet crossed it. For laboratory researchers cataloguing compounds in this space, our MOTS-c 10mg reference page collects sequence and handling data, and our research dosing calculator can help with reconstitution mathematics for in-vitro work.
Frequently asked questions
Is MOTS-c the same as SS-31?
No. Both are mitochondria-related peptides studied in longevity research, but they differ in structure and mechanism. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that activates AMPK signalling. SS-31 is a synthetic four-amino-acid peptide that binds cardiolipin to stabilise the inner mitochondrial membrane. They are investigated for related goals through different pathways.
Does exercise increase MOTS-c naturally?
Research suggests yes. In the Reynolds 2021 study, an acute bout of cycling raised MOTS-c messenger RNA in human skeletal muscle roughly 12-fold and increased circulating levels around 1.6-fold. This exercise-responsiveness is a major reason MOTS-c is studied as a possible molecular link between physical activity and metabolic health.
Is there human clinical evidence for MOTS-c?
Human evidence is limited and early. Most robust findings come from mouse and cell studies. Small human data exist, largely involving engineered MOTS-c analogues rather than the native peptide, and results remain preliminary. No regulator has approved MOTS-c, and it is not a licensed medicine in the EU or elsewhere.
How does MOTS-c relate to insulin sensitivity?
In animal models, MOTS-c improves insulin-stimulated glucose uptake, particularly in skeletal muscle, and reduces diet- and age-related insulin resistance. The proposed mechanism runs through AMPK activation and altered folate-cycle metabolism. Whether these effects translate to meaningful human outcomes has not been established in large clinical trials.
Why do MOTS-c levels fall with age?
Observational studies in mice and humans show circulating MOTS-c declines with chronological age, with notably lower levels reported in older versus younger men. The exact drivers are not fully understood but likely reflect broader age-related decline in mitochondrial function and biogenesis. This age-related drop is one reason MOTS-c attracts longevity-research interest.
Is MOTS-c legal to use?
MOTS-c is sold and handled as a research chemical for laboratory use only and is not an approved medicine anywhere. It is not authorised for human treatment in the EU. Additionally, the World Anti-Doping Agency added MOTS-c to its Prohibited List in January 2024, which is relevant for anyone subject to sport testing.
References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470.
- Kim SJ, Miller B, Mehta HH, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports. 2019;7(13):e14171.
- Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023;14:1120533.
- Merry TL, Chan A, Woodhead JST, et al. Mitochondrial-derived peptides in energy metabolism. American Journal of Physiology-Endocrinology and Metabolism. 2020;319(4):E659-E666.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014;171(8):2029-2050.
Research-use-only disclaimer: This article is educational and describes preclinical and early research. MOTS-c is not an approved medicine and is intended for laboratory research use only. Nothing here is medical advice or a dosing, therapeutic, or human-use recommendation. Always follow applicable EU and national regulations.